7 recruiting. 7 Phase 2, 3 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Recruiting 7 |
| Phase 1 | 3 | Recruiting 3 |
| Phase 3 | 1 | Recruiting 1 |
Follow Myelitis: new trials by email Literature Review of Myelitis trials Research Report on Myelitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase I/II Clinical Trial of the Diphtheria, Tetanus, Acellular Component Pertussis and Sabin Inactivated Poliomyelitis Vaccine Adsorbed Diphtheria, Tetanus, Acellular Component Pertussis and Sabin Inactivated Poliomyelitis Vaccine Adsorbed, Diphtheria, Tetanus and Acellular Component Pertussis Combined Vaccine, Diphtheria, Tetanus and Acellular Component Pertussis Combined Vaccine+Inactivated Poliomyelitis Vaccine Made From Sabin Strains - Diphtheria, Pertussis | Phase 1 / Phase 2 | Recruiting | Institute of Medical Biology, Chinese Academy of Medical Sciences | 380 | 2026-10-11 | 2026-10-23 |
| Dolutegravir Versus Dolutegravir in Combination With Tenofovir for the Treatment of HTLV-1 Infection Combination of Dolutegravir + Tenofovir DF for treatment of HTLV-1 infection, Dolutegravir (DTG) - HTLV-1 Infection, HTLV I Associated Myelopathies | Phase 2 | Recruiting | Carlos Brites | 146 | 2026-05-07 | 2026-06-02 |
| Study of Co-administered (Types 1 & 2) Novel Oral Poliomyelitis Vaccines Evaluation Novel Oral Polio Vaccine Type 1 (nOPV1), Novel Oral Polio Vaccine Type 2 (nOPV2), Placebo (Sterile Water) - Poliomyelitis | Phase 2 | Recruiting | PATH | 675 | 2025-11-11 | 2026-01-09 |
| Study of Trivalent and Bivalent (Types 1 & 2) Novel Oral Poliomyelitis Vaccines Novel oral poliomyelitis vaccine type 1 (nOPV1), Novel oral poliomyelitis vaccine type 2 (nOPV2), Novel oral poliomyelitis vaccine type 3 (nOPV3) - Poliomyelitis | Phase 1 / Phase 2 | Recruiting | PATH | 2400 | 2024-11-20 | 2025-06-03 |
| Study of a Novel Type 3 Oral Poliomyelitis Vaccine in Panama Novel Live Attenuated Type 3 Oral Poliomyelitis Vaccine (nOPV3), Sabin Monovalent Oral Poliomyelitis Vaccine Type 3 (mOPV3) - Poliomyelitis | Phase 2 | Recruiting | PATH | 1532 | 2023-12-05 | 2026-05-11 |
| Open-label, Long-term Safety, Efficacy, and Pharmacokinetics Study of Vibegron in Pediatric Subjects 2 Years to < 18 Years of Age With NDO and on CIC Vibegron - Neurogenic Detrusor Overactivity | Phase 2 / Phase 3 | Recruiting | Urovant Sciences GmbH | 71 | 2022-10-12 | 2026-06-15 |
| Study to Investigate the Safety of the Transplantation of Human Glial Restricted Progenitor Cells Into Subjects With Transverse Myelitis Q-Cells - Transverse Myelitis | Phase 1 / Phase 2 | Recruiting | Q Therapeutics, Inc. | 9 | 2022-09-20 | 2026-07-21 |
Poliomyelitis (4) · Myelitis, Transverse (2) · Diphtheria (1) · HTLV-I Infections (1) · Leukemia-Lymphoma, Adult T-Cell (1) · Meningocele (1) · Meningomyelocele (1) · Neuritis (1) · Paraparesis, Tropical Spastic (1) · Spinal Cord Injuries (1) · Spinal Dysraphism (1) · Tetanus (1) · Whooping Cough (1)
Central Nervous System Diseases (7) · Central Nervous System Infections (7) · Infections (7) · Nervous System Diseases (7) · Neuroinflammatory Diseases (7) · Spinal Cord Diseases (7) · Neuromuscular Diseases (5) · RNA Virus Infections (5) · Virus Diseases (5) · Enterovirus Infections (4) · Picornaviridae Infections (4) · Immune System Diseases (3) · Neoplasms (3) · Autoimmune Diseases (2)
N-(4-((5-(hydroxy(phenyl)methyl)pyrrolidin-2-yl)methyl)phenyl)-4-oxo-4,6,7,8-tetrahydropyrrolo(1,2-a)pyrimidine-6-carboxamide (1) · Tenofovir (1) · Tetanus Toxoid (1) · dolutegravir (1)
PATH (3) · Carlos Brites (1) · Institute of Medical Biology, Chinese Academy of Medical Sciences (1) · Q Therapeutics, Inc. (1) · Urovant Sciences GmbH (1)
Panama (2) · United States (2) · Bangladesh (1) · Belgium (1) · Brazil (1) · Canada (1) · China (1) · Croatia (1) · Denmark (1) · Georgia (1) · Jordan (1) · Latvia (1) · Lithuania (1) · Malaysia (1) · Philippines (1)
Benjamin Greenberg, MD (1) · Carlos Brites, MD, PhD (1) · Janet Owens-Grillo (1) · Wenge Tang (1) · Xavier Saez Llorens, MD (1) · Xavier Saez-Llorens, MD (1)